(UroToday.com) Dr. Laura Marandino, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy presented “Cabozantinib plus durvalumab in patients with advanced urothelial carcinoma after platinum chemotherapy: safety and preliminary activity of the open-label, single-arm, phase 2 ARCADIA trial.” As single agents, both durvalumab and cabozantinib have efficacy in advanced urothelial carcinoma.